Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 11687 in total
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout...
Approved
Matched Description: … Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. ... a post-market clinical study (the CARES trial) where there was an increased risk of cardiovascular ( ... [A230548] In February 2019, a black box warning for febuxostat was added, based on the findings of …
Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II,...
Approved
Investigational
Matched Description: … Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. ... [L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates …
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in...
Approved
Matched Description: … A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed …
The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII). Exogenous sources of vWF...
Approved
Investigational
Matched Description: … The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma ... vWF products are also available as a combination product with [antihemophilic factor human]. ... It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood …
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Approved
Investigational
Withdrawn
Matched Description: … associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Description: … Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. ... Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of …
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term ... a different glycosylation pattern. ... the deficiency of alpha-galactosidase A. …
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Description: … kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. ... While patients generally do not experience a clinically significant difference in outcomes between the ... A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the...
Approved
Investigational
Matched Description: … [L1292] In the US, it presents a Status class I by the FDA. ... It is used in the UK as a treatment for migraine under the name of Clotam. ... Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory …
Poa annua pollen is the pollen of the Poa annua plant. Poa annua pollen is mainly used in allergenic testing.
Approved
Iva annua pollen is the pollen of the Iva annua plant. Iva annua pollen is mainly used in allergenic testing.
Approved
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis...
Approved
Matched Description: … [L47526] It is considered one of the most likely agents to be used in a biological attack. ... Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high ... microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.
Approved
Approved
Investigational
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Description: … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid …
Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections , . Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils . The acute sore throat (pharyngitis)...
Approved
Matched Description: … Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the …
Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor...
Approved
Matched Description: … co-factor to Factor IX. ... Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant ... in the Factor VIII gene, leading to a functional deficiency or complete loss of protein. …
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown …
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … a deficiency in GAA. ... Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. ... Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Bifonazole is an azole antifungal drug.
Approved
Investigational
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear,...
Approved
Investigational
Matched Description: … It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, …
Displaying drugs 676 - 700 of 11687 in total